Parkinson’s disease affects an estimated 6.1 million people worldwide and roughly 1.04 million Americans, and its hallmark is the progressive death of dopamine-producing neurons in the substantia nigra and striatum. Because the symptoms of tremor, rigidity, bradykinesia and gait disturbance stem largely from dopamine depletion, most current drug strategies attempt to restore dopaminergic signaling. Levodopa therapy remains the gold standard, but long-term use brings considerable complications, so clinicians often pair it with monoamine oxidase B inhibitors such as selegiline. These inhibitors block the flavin-dependent enzyme MAO-B, which breaks down dopamine in the brain, thereby preserving the neurotransmitter and easing motor symptoms. The problem is that existing MAO-B inhibitors carry a heavy burden of side effects, including nausea, insomnia, orthostatic hypotension, hallucinations, serotonin syndrome in severe cases and worsening dyskinesia when combined with levodopa. Safer, more selective alternatives are urgently needed.

The research team turned to nature’s pharmacy. Phytochemicals, and polyphenols in particular, have repeatedly shown antioxidant, anti-inflammatory and neuroprotective properties relevant to neurodegenerative diseases, and piperine has a growing preclinical track record spanning neuroprotective, anticonvulsant and antidepressant effects. Crucially, earlier laboratory work had already shown that piperine can inhibit MAO enzymes directly: one experimental study reported IC50 values of 20.9 micromolar for MAO-A and 7 micromolar for MAO-B, while another documented mixed-type inhibition of MAO-A and competitive inhibition of MAO-B. Derivatives of piperine have shown even more striking selectivity, with one compound inhibiting MAO-B at an IC50 of just 0.045 micromolar. What remained missing was a rigorous, atomistic account of how piperine engages the MAO-B active site and whether that engagement is stable enough to matter therapeutically.

To answer that question, the researchers first docked piperine, whose structure was quantum-mechanically optimized using the B3LYP functional with a 6-31G** basis set, into the crystal structure of human MAO-B, the well-characterized PDB entry 2BYB. Using AutoDock 4.2 with a two-stage blind-and-focused protocol and 200 independent Lamarckian Genetic Algorithm runs, they computed a binding free energy of −9.23 kcal/mol for piperine, substantially better than the −6.3 kcal/mol recorded for Deprenyl. The docked pose placed piperine squarely in the hydrophobic cavity adjacent to the FAD cofactor, forming multiple hydrogen bonds with essential amino acids while its flat, aromatic rings engaged in the kind of pi-pi stacking and hydrophobic contacts that drive high-affinity ligand binding in this enzyme.

Docking, however, is only a static snapshot. To test whether the complex survives the thermal chaos of a real cellular environment, the team ran molecular dynamics simulations in GROMACS 2022.6 with the Amber99SB force field, explicitly solvating the systems in TIP3P water with 0.15 M physiological salt and crucially performing three independent 200-nanosecond replicates per system to capture statistical variability. The results were consistent and telling. The average root mean square deviation of the protein backbone was 0.219 ± 0.017 nm for the MAO-B-piperine complex, tighter than both the free protein at 0.281 ± 0.008 nm and the Deprenyl complex at 0.227 ± 0.002 nm, indicating that piperine binding actually stabilizes the enzyme scaffold. Root mean square fluctuation, radius of gyration and solvent accessible surface area analyses all reinforced the same picture: the piperine-bound system remained compact, stable and free of unfolding across the full simulation window.

The hydrogen bond and contact analyses added further weight. Over 200 nanoseconds, the piperine complex maintained an average of 407 ± 3 protein-protein hydrogen bonds and roughly 2248 ± 15 protein-ligand contacts, versus about 1810 ± 76 contacts for Deprenyl, and the protein-ligand distance held steady near 0.2 nm throughout. Principal component analysis showed that the first two eigenvectors accounted for just over half of the total motion in every system, and that binding piperine constrained and clustered the protein’s motions compared with the free enzyme. The free energy landscape, plotted along the first two principal components, revealed a single deep global minimum for the piperine complex with no signs of aberrant conformational excursions, confirming that the ligand locks the enzyme into a thermodynamically settled state.

The energetic accounting sealed the case. Using the MM-PBSA method, the team calculated a total binding free energy of −142.12 ± 11.34 kJ/mol for the MAO-B-piperine complex against −86.21 ± 11.15 kJ/mol for MAO-B-Deprenyl, with van der Waals forces the dominant favorable contribution. The authors are careful to note an important limitation: Deprenyl is an irreversible inhibitor whose clinical power comes from forming a covalent bond with the FAD cofactor, a step not modeled here, so the comparison reflects noncovalent binding components rather than a direct measure of inhibitory potency in the clinic. Even so, within that framework, piperine’s noncovalent engagement of the MAO-B cavity proved decisively more favorable.

The study also probed the electronic heart of the interaction using density functional theory at the B3LYP/6-311++G(d,p) level. Piperine’s HOMO-LUMO energy gap of 3.76 eV was considerably smaller than the 5.39 eV of the Deprenyl cocrystal system, translating into lower chemical hardness (1.88 versus 2.70), higher softness (0.53 versus 0.37) and a much larger electrophilicity index (3.96 versus 1.82 eV). By the conceptual DFT and hard-soft acid-base logic, a softer, more polarizable molecule like piperine can rearrange its electron density more readily in response to the electrostatic field of the enzyme’s active site, enabling stronger orbital overlap with the electron-rich aromatic residues lining the binding pocket. Its substantially higher dipole moment of 4.46 Debye, versus 0.49 for the cocrystal system, further supports strong orientation-dependent interactions at the binding interface.

Perhaps most importantly for drug development, piperine’s pharmacokinetic profile is genuinely encouraging. SwissADME and pkCSM predictions showed that piperine passes Lipinski’s rule of five with zero violations and also clears the Ghose, Veber, Egan and Muegge filters, with high gastrointestinal absorption and predicted blood-brain barrier permeability, the single most essential property for a central nervous system drug. These predictions align with experimental evidence: in vitro models of the blood-brain barrier have shown piperine achieving the highest penetration among tested analogs, and rat pharmacokinetic studies after oral dosing found a brain-to-plasma concentration ratio near unity, high affinity for brain tissue and rapid, significant brain uptake. In SH-SY5Y neuronal cells, piperine showed no significant toxicity at concentrations up to 40 micromolar and protected the cells against chemically induced damage at moderate doses, hinting at a genuine neuroprotective window.

The caveats are real and the authors state them plainly. Piperine is a known inhibitor of CYP3A4 and P-glycoprotein, which means it can amplify the levels of other medications, a serious concern for Parkinson’s patients who typically take multiple drugs. This study, for all its methodological depth, remains entirely computational, and piperine’s in vivo inhibition of MAO-B at achievable brain concentrations has not yet been demonstrated in animal models or patients. Still, the convergence of docking affinity, simulation stability, binding energetics, favorable quantum chemical reactivity and an experimentally validated brain-penetrant pharmacokinetic profile makes a rare, internally consistent case. If future laboratory and clinical work confirms these predictions, a molecule borrowed from the kitchen spice rack could become the scaffold for a new generation of safer, better-tolerated Parkinson’s therapies.

Subject of Research: MAO-B inhibition for Parkinson's disease using the natural compound piperine, evaluated through molecular docking, molecular dynamics simulation, DFT analysis and pharmacokinetic prediction

Article Title: Therapeutic strategy for Parkinson's disease through MAO-B inhibition by a novel compound: MD simulation, DFT analysis and pharmacokinetic study

Article References: Baziyar, P., & Emamzadeh, R. (2026). Therapeutic strategy for Parkinson's disease through MAO-B inhibition by a novel compound: MD simulation, DFT analysis and pharmacokinetic study. Results in Chemistry, 30, Article 103837. https://doi.org/10.1016/j.rechem.2026.103837

Image Credits: AI Generated

DOI: 10.1016/j.rechem.2026.103837

Keywords: Parkinson's disease, piperine, MAO-B inhibitor, molecular dynamics simulation, molecular docking, DFT analysis, MM-PBSA, pharmacokinetics, neurodegenerative disease, black pepper, dopamine, drug discovery

The review, authored by Vihanga Kularatne, Naba Kumar Dutta, Nevena Todorova and Namita Roy Choudhury of the School of Engineering at RMIT University in Melbourne, Australia, focuses on graphene-based nanomaterials, or GNMs, as fillers for elastomer matrices. Graphene, a single sheet of carbon atoms arranged in a honeycomb lattice, and its chemically modified relatives such as graphene oxide combine exceptional intrinsic stiffness, high surface area, and tunable surface chemistry in a filler whose individual sheets are only one atom thick. Dispersed even at low loadings within a rubbery matrix, these sheets promise dramatic gains in modulus, tensile strength, wear resistance, thermal conductivity and barrier performance. The catch, the authors emphasise, is that none of those gains is guaranteed. Everything depends on what happens at the nanoscale interface where polymer chains meet the carbon surface, a region far too small and too fast for most laboratory techniques to observe directly.

This is where molecular dynamics simulations enter the picture. By solving Newton’s equations of motion for every atom in a modelled system, molecular dynamics allows researchers to watch, atom by atom, how polymer chains adsorb onto graphene surfaces, how they wrap around filler sheets, how filler particles aggregate or separate, and how stress is transferred from the soft matrix into the stiff reinforcement. While several previous reviews have catalogued the experimental literature on graphene-filled elastomers, the RMIT team identifies a significant gap: no comprehensive synthesis has pulled together specifically the computational modelling studies. Their review fills that gap by critically examining what simulations have revealed about interfacial interaction mechanisms, filler compatibility and dispersion, mechanical and tribological behaviour, thermal transport, barrier properties, and the practical matters of force field selection and validation.

One of the central themes running through the review is the decisive role of interfacial chemistry. Pristine graphene is chemically inert, and in a nonpolar elastomer it interacts with polymer chains mainly through weak van der Waals forces. Graphene oxide, by contrast, carries oxygen-containing functional groups such as hydroxyl, epoxy and carboxyl moieties across its surface, which can hydrogen-bond with polar elastomer segments and dramatically alter how strongly chains adsorb to the filler. Simulations show that the strength of this adsorption governs the formation of bound polymer layers around filler sheets, the mobilisation of chain segments near the interface, and ultimately how efficiently stress is transferred into the reinforcement. Too little interaction and the filler simply slips within the matrix, contributing little; carefully tuned interaction creates an immobilised interphase that behaves almost like a third material between filler and bulk polymer, stiffening the composite and slowing the diffusion of small molecules through it.

Dispersion is the second pillar of performance, and simulations have been particularly revealing here. Because individual graphene sheets have an enormous tendency to restack due to π-π interactions between their faces, achieving a uniform distribution within a viscous elastomer melt is one of the great practical challenges of the field. Molecular dynamics studies allow researchers to quantify aggregation behaviour directly, tracking how functionalisation, matrix chemistry and processing-relevant parameters influence whether filler sheets remain separated or clump into structures that behave more like defects than reinforcements. The review highlights that compatibility between the filler surface and the specific elastomer chemistry is what determines the outcome, which explains why a loading that transforms one rubber may do little for another.

The matrices examined in detail reflect the industrial heart of the elastomer sector. Natural rubber, valued for its unmatched combination of strength and elasticity; styrene-butadiene rubber, the workhorse of tyre treads; nitrile-butadiene rubber, prized for oil resistance in seals and hoses; and thermoplastic polyurethane, which bridges the gap between rubbers and processable plastics, each present distinct chain chemistries and therefore distinct interfacial behaviours with graphene-based fillers. Simulations comparing these systems show how the polarity of the backbone, the presence of aromatic groups, and the density of potential hydrogen-bonding sites all reshape the interaction landscape at the filler surface. By comparing simulation findings with experimental observations, the review identifies where theory and experiment agree cleanly, where discrepancies persist, and where the limitations of current models, including finite simulation timescales and simplified chemistries, still constrain predictive confidence.

Beyond stiffness and strength, the review surveys what simulations have taught the field about tribological properties, the friction and wear behaviour that determines how long a tyre tread or a dynamic seal survives in service. Graphene’s lubricating character and its ability to form protective transfer layers make it an attractive anti-wear additive, and atomistic models have begun to clarify how filler orientation, coverage and interfacial bonding control the material response to sliding contact. Thermal transport represents another frontier: graphene’s intrinsic thermal conductivity is extraordinary, but simulations reveal that the thermal boundary resistance at the filler-polymer interface, together with the quality of network formation between filler sheets, largely dictates how much of that conductivity survives in the composite. Barrier properties, similarly, emerge from simulations as a tortuosity problem, with well-dispersed, oriented sheets forcing diffusing gas molecules to follow long winding paths around impermeable carbon plateaus, dramatically slowing permeation in applications such as inner tubes and pressurised bladders.

A distinctive contribution of the review is its frank treatment of methodology. Force fields, the mathematical descriptions of interatomic interactions at the heart of any molecular dynamics study, differ substantially in how they treat carbon allotropes, polymer chains and cross-links, and the choice among them can change predicted interfacial energies and mechanical responses by meaningful margins. The authors stress that appropriate force field selection, and systematic validation against experimental data, are not optional refinements but prerequisites for simulations that genuinely guide materials design. This methodological honesty, they argue, is what will allow the growing simulation literature to mature from qualitative illustration into a quantitative, molecular-level framework for engineering elastomer nanocomposites, connecting the structure of a graphene sheet and the chemistry of an elastomer chain to the mechanical, tribological, thermal and barrier performance of the finished material.

The significance of such a framework extends well beyond the laboratory. Reinforced elastomers underpin transportation, energy, aerospace and consumer industries, and improvements in filler efficiency translate directly into longer-lasting tyres, more reliable seals, lighter components and reduced material consumption. By consolidating what two decades of atomistic modelling have established, and by flagging where the computational evidence remains thin, the RMIT review offers researchers a map of the field’s current understanding and its open questions. As computational power grows and force fields grow more accurate, the prospect of designing a rubber composite in silico, choosing the filler chemistry and loading that precisely match the target application before the first batch is mixed, moves from aspiration toward practical reality. For a class of materials that has been reinforced largely by empirical trial and error for more than a century, that would represent a genuinely molecular revolution.

Subject of Research: Molecular dynamics simulation insights into graphene-filled elastomer nanocomposites

Article Title: Elastomer nanocomposites filled with graphene-based nanomaterials: insights from molecular dynamics simulations

Article References: Kularatne, V., Dutta, N. K., Todorova, N., & Choudhury, N. R. (2026). Elastomer nanocomposites filled with graphene-based nanomaterials: insights from molecular dynamics simulations. Advanced Composites and Hybrid Materials. https://doi.org/10.1007/s42114-026-02047-4

Image Credits: AI Generated

DOI: 10.1007/s42114-026-02047-4

Keywords: elastomer nanocomposites, graphene-based nanomaterials, molecular dynamics simulations, graphene oxide, interfacial interactions, polymer-filler compatibility, natural rubber, barrier properties, tribological properties, force field selection, thermal transport, structure-property relationships

The research, led by Hafs Essaadi and colleagues at Mohammed V University in Rabat, Morocco, together with collaborators at the Mohammed VI Center for Research and Innovation and UM6SS, focused on the viral 3C protease, an enzyme designated 3Cpro that is indispensable to the rhinovirus life cycle. After the virus infects a cell, its genome is translated into a single long polyprotein that must be cleaved into functional viral proteins, and the 3C protease performs most of these cuts. Because the catalytic architecture of 3Cpro is highly conserved across human rhinovirus species, a molecule that disables it could in principle suppress a wide range of rhinovirus strains, making the enzyme an attractive therapeutic target.

To find candidate inhibitors, the team screened a library of 49,437 compounds against the 3C protease of human rhinovirus species C, the rhinovirus group most frequently associated with severe asthma exacerbations. The docking calculations were carried out with AutoDock Vina, a widely used molecular docking engine that predicts how small molecules orient themselves within a protein binding pocket and estimates the binding affinity of each pose. The researchers then applied ADMET-based prioritization, filtering the top-scoring hits for acceptable absorption, distribution, metabolism, excretion, and toxicity profiles, a step designed to weed out compounds that might bind well in silico but fail as drug candidates.

The docking analysis converged on two lead compounds that occupied the catalytic pocket of the protease in orientations predicted to be highly favorable. Both molecules formed stabilizing interactions with key residues of the active site, including His40, Glu71, and Cys147, the latter being the catalytic cysteine that sits at the heart of the enzyme’s cleavage chemistry. When compared with rupintrivir, the best-known experimental rhinovirus 3C protease inhibitor, which functions as an irreversible covalent inhibitor, the two new compounds achieved comparable or better engagement of the catalytic site without forming covalent bonds, a property that could translate into improved safety profiles.

Docking scores alone are a crude measure of binding, so the team subjected the protein-ligand complexes to molecular dynamics simulations lasting 200 nanoseconds each, allowing the atoms to move under realistic physical forces and revealing whether the predicted binding poses remain stable over time. Both compounds stabilized the protease relative to the unbound, or apo, form of the enzyme. Compound 1 produced the lowest protein root-mean-square deviation, holding the overall structure of the protease at 1.21 plus or minus 0.22 angstroms from its starting conformation, while compound 2 yielded the lowest root-mean-square fluctuation for the critical Cys147 residue, at just 0.48 angstroms, indicating that the catalytic nucleophile itself was held unusually rigid in the presence of this ligand.

Ligand mobility within the binding pocket provided further evidence of durable binding. Over the course of the simulations, compound 1 displayed a ligand RMSD of 1.49 plus or minus 0.78 angstroms and compound 2 a value of 2.01 plus or minus 0.39 angstroms, whereas rupintrivir wandered considerably more, with a ligand RMSD of 4.83 plus or minus 0.89 angstroms. Lower ligand RMSD values indicate that a molecule stays anchored in its original binding pose rather than drifting or partially exiting the pocket, suggesting that the two new candidates maintain more persistent contact with the active site than the reference inhibitor under dynamic conditions.

To quantify binding strength more rigorously, the researchers applied the MM/PBSA method, which combines molecular mechanics energies with solvation models to estimate the free energy of binding from simulated trajectories. Both leads outperformed rupintrivir on this metric: compound 1 achieved an effective binding energy of minus 23.59 plus or minus 6.87 kilocalories per mole, and compound 2 reached minus 25.25 plus or minus 5.75 kilocalories per mole, compared with minus 19.43 plus or minus 4.46 kilocalories per mole for rupintrivir. The team complemented these calculations with free energy landscape analysis, a technique that maps the conformational states sampled during simulation and identifies the most thermodynamically stable configurations of each complex, providing an additional layer of confidence that the observed binding modes represent genuine energetic minima rather than transient artifacts.

The significance of a non-covalent mechanism deserves emphasis. Rupintrivir, which reached phase II clinical trials as a nasal spray, irreversibly modifies the catalytic cysteine, and while this reactivity underlies its potency, covalent inhibitors can raise concerns about off-target modification of human enzymes that rely on similar cysteine chemistry. Compounds that achieve strong binding through reversible, non-covalent interactions, as the two leads reported here appear to do, may offer a wider therapeutic window. The ADMET filtering applied during the study further suggests that the candidates were selected not only for potency but also for drug-like behavior, although the authors stress that computational predictions of this kind require experimental confirmation.

Indeed, the study stops short of laboratory validation, and the authors are explicit that compounds 1 and 2 should be regarded as promising candidates for further experimental testing rather than proven antivirals. Enzyme inhibition assays, antiviral activity measurements in infected cell cultures, and eventually pharmacokinetic and toxicity studies in vivo will be needed to determine whether the computational promise translates into real therapeutic value. The data generated during the study are available from the corresponding author upon request, and the work was supported in part by computational resources from the Pediatric Translational Clinical Research Unit.

Nevertheless, the study adds to a growing body of evidence that structure-based computational screening can accelerate antiviral discovery against rhinoviruses, a pathogen family that has historically frustrated drug developers because of its antigenic diversity. By anchoring the search on a conserved, essential enzyme and validating hits through a multi-layered pipeline of docking, long-timescale dynamics, free energy landscape mapping, MM/PBSA energetics, and ADMET profiling, the Moroccan team has delivered a shortlist of chemically tractable starting points. If subsequent experiments bear out the predicted potency of these molecules, the work could represent an early but meaningful step toward the first effective antiviral treatment for the infections that trigger many of the world’s asthma attacks and common colds.

Subject of Research: Computational discovery of non-covalent inhibitors targeting the human rhinovirus 3C protease

Article Title: Computational discovery of novel human rhinovirus 3 C protease inhibitors: molecular docking, dynamic simulations, free energy landscape, MMPBSA and ADMET analysis

Article References: Essaadi, H., Chourir, A., Kourou, J., Makhloufi, F., Hachlaf, O., Abidou, A., Boutayeb, S., Eljaoudi, R., Belyamani, L., Ibrahimi, A., Hakmi, M., & Hafidi, N. E. (2026). Computational discovery of novel human rhinovirus 3 C protease inhibitors: molecular docking, dynamic simulations, free energy landscape, MMPBSA and ADMET analysis. Molecular Diversity. https://doi.org/10.1007/s11030-026-11704-1

Image Credits: AI Generated

DOI: 10.1007/s11030-026-11704-1

Keywords: human rhinovirus, 3C protease, antiviral drug discovery, molecular docking, molecular dynamics simulations, MM/PBSA, free energy landscape, ADMET analysis, virtual screening, rupintrivir, common cold, asthma exacerbation

Led by Shivangi Sharma, with Pragya D. Yadav and Sarah Cherian as senior authors, the research team assembled a training dataset of 211 compounds drawn from three publicly curated sources: the Anti-Nipah database, the Nipah Virus Inhibitor Knowledgebase (NVIK), and PubChem, supplemented by a systematic review of the literature. This dataset contained both known inhibitors and inactive compounds, providing the labeled examples needed for supervised learning. Each molecule was converted into a numerical fingerprint using molecular descriptors calculated with the Mordred software, capturing features such as molecular weight, topological indices, electronic properties and atom-type electrotopological states. These descriptors serve as the language through which algorithms perceive chemical structure, allowing a model to learn which patterns of atoms, bonds and charge distributions correlate with antiviral activity against Nipah virus.

The investigators benchmarked seven different supervised machine learning algorithms: Support Vector Machines, Random Forest, Logistic Regression, Decision Tree, k-Nearest Neighbors, Artificial Neural Networks, and Ridge Classifier. Each was trained and evaluated using standard performance metrics, including accuracy, receiver operating characteristic analysis, and the Matthews correlation coefficient, a measure favored in cheminformatics because it remains robust even when classes are imbalanced. Among all seven, the Random Forest model, an ensemble method that aggregates the votes of hundreds of decision trees each trained on random subsets of the data, emerged as the clear winner. It achieved 95 percent accuracy on the training data and, critically, 86 percent on the held-out test set, indicating that the model had learned generalizable chemical patterns rather than simply memorizing its training examples. This balance between training and testing performance is the crucial test of any predictive model, and the Random Forest classifier passed it convincingly.

With a validated model in hand, the team unleashed it on a massive virtual haystack. The screening library comprised 9,021 compounds spanning FDA-approved drugs, molecules in preclinical development, investigational agents in clinical trials, and a dedicated collection of known antivirals. This breadth is the essence of drug repurposing: rather than spending a decade and billions of dollars synthesizing and testing novel chemicals, researchers can ask whether a molecule already optimized for safety, pharmacokinetics and manufacturability might also inhibit a new target. For a virus like Nipah, whose outbreaks are sporadic and unpredictable, the speed advantage is decisive. The machine learning classifier assigned each compound a probability of anti-Nipah activity, and the highest-scoring molecules advanced to the next stage of the pipeline.

That next stage was structural. The researchers focused on two of the virus’s most critical proteins: the attachment glycoprotein G, which sits on the viral surface and latches onto ephrin-B2 and ephrin-B3 receptors on human cells, initiating the entry process; and the RNA-dependent RNA polymerase (RdRp), the L-P protein complex that copies the viral genome and is essential for replication. Blocking either target can cripple the virus, and recent cryo-electron microscopy structures of the Nipah polymerase complex have finally given computational scientists an accurate map to work from. Using the Glide docking engine and the OPLS4 force field, the team computed binding poses and affinity scores for the shortlisted candidates within the binding pockets of both proteins, after careful preparation of protonation states and protein geometry.

Docking scores alone can be misleading, so the researchers added a second layer of physical rigor: molecular dynamics simulations. These simulations, run on the NAKSHATRA high-performance computing facility developed under India’s PM-Ayushman Bharat Health Infrastructure Mission, allow the protein-ligand complexes to flex and move in a simulated aqueous environment over time. A compound that binds well in a static docked pose but falls out of the binding pocket during dynamic simulation is unlikely to be a real inhibitor. By monitoring structural stability, root-mean-square deviations and persistent intermolecular contacts, the team separated genuine binders from computational artifacts.

The final verdict yielded eight candidate molecules, distributed across the two targets. Against the glycoprotein, three compounds stood out: 2,3,4,5,6-pentagalloylglucose (PGG), echinacoside, and parishin A. Against the RNA-dependent RNA polymerase, five compounds showed stable, high-affinity binding: neohesperidin dihydrochalcone, naringin dihydrochalcone, diosmin, orientin, and amikacin. Several of these names will be familiar to natural products chemists. PGG, a heavily galloylated tannin found in oak bark and various medicinal plants, has previously been shown to block influenza A virus and to inhibit the interaction between the SARS-CoV-2 spike protein and the human ACE2 receptor. Echinacoside, derived from Echinacea species, has documented antiviral activity against respiratory viruses and was recently flagged in computational studies against the Zika virus polymerase. Parishin A, a bioactive constituent of the orchid Gastrodia elata, has similarly been implicated in blocking viral entry in prior structural studies.

The polymerase-directed candidates are equally intriguing. Neohesperidin dihydrochalcone is, remarkably, a widely used artificial sweetener approved as a food additive in many countries, and it carries an extensive safety dossier along with documented anti-inflammatory and antioxidant properties; it has also been docked against SARS-CoV-2 proteins in earlier work. Diosmin, a flavonoid used as a vascular tonic in human medicine, has recently demonstrated antiviral potential against influenza A. Orientin, a luteolin glycoside found in passionflower and other botanicals, has been studied experimentally against the SARS-CoV-2 spike protein. Amikacin is the most surprising entry on the list: an aminoglycoside antibiotic in clinical use for decades, it belongs to a drug class that has been shown in independent research to enhance host resistance to viral infections through microbiota-independent mechanisms. Its strong binding to the Nipah polymerase adds a completely new dimension to its potential therapeutic profile.

The choice of targets reflects a deep understanding of Nipah virus biology. The G glycoprotein is the virus’s key to the cell, and its receptor-binding domain has been mapped at atomic resolution in multiple crystal structures, revealing precisely which residues engage ephrin-B2. Antibodies and small molecules that occlude this interface prevent attachment and fusion. The polymerase, meanwhile, is the engine of viral replication, and it has proven to be an Achilles’ heel for related paramyxoviruses: allosteric polymerase inhibitors developed against measles virus and respiratory syncytial virus suppress all RNA synthesis activity in those pathogens. A recent non-nucleotide allosteric inhibitor with pan-coronavirus activity has further demonstrated that polymerase targets can yield broad-spectrum antivirals, making the Nipah L-P complex a highly strategic point of attack. The availability of the cryo-EM structure of the Nipah L-P complex, published in late 2024, transformed this target from an aspirational goal into a practical docking substrate.

The current standard of care for Nipah infection remains rudimentary. Ribavirin, used empirically during the 1998-1999 Malaysian outbreak, showed only ambiguous benefit in observational studies of acute encephalitis patients. The monoclonal antibody m102.4, which neutralizes the G glycoprotein, has been administered on a compassionate basis but is not licensed. Remdesivir and favipiravir both protect animals in challenge experiments, and remdesivir has been tested in compassionate-use settings, yet neither is an approved Nipah therapy. Vaccine development is accelerating: a recombinant vesicular stomatitis virus vector vaccine has advanced toward human trials in outbreak regions, and the University of Oxford launched the world’s first Phase II Nipah vaccine trial with CEPI support. But vaccines alone cannot treat established infections, and the unpredictable geography of spillovers from fruit bats to humans through contaminated date palm sap or direct animal contact means that a stockpiled, orally available antiviral would be an invaluable component of outbreak preparedness.

The authors emphasize that their integrative approach, combining machine learning prediction with structure-based validation, is designed precisely to compress the timeline between an outbreak’s emergence and the availability of candidate therapeutics. Because every compound that survived the pipeline already exists in the pharmacopeia, at least in some form, downstream development could in principle bypass many early-stage hurdles of traditional drug discovery. The team also notes that all data used in the study are publicly available, and the models were built entirely from open resources, a transparency that should allow other groups to reproduce, refine and extend the approach.

Caveats remain, as they do for all purely computational studies. Docking and molecular dynamics predictions must ultimately be confirmed in live-virus assays, which require high-containment BSL-4 laboratories, and subsequently in animal models and human trials. Physicochemical liabilities, metabolic stability and oral bioavailability of the larger natural-product-derived molecules will need careful evaluation using tools such as SwissADME and ADMETlab, both of which the authors employed in their computational assessment. Nevertheless, the study stands as a template for how artificial intelligence can transform the response to neglected, high-consequence pathogens. By converting scattered inhibitor data into a predictive engine and then filtering thousands of real-world drugs through docking and dynamics, the Pune team has handed the Nipah research community a short, chemically diverse and mechanistically grounded list of candidates worth testing the moment the next outbreak appears. In a field where every month of delay can cost lives, that kind of head start could prove invaluable.

The study, led by Hossam M. Abdallah of King Abdulaziz University in Jeddah, together with Mohamed A. Farag of Cairo University and colleagues, integrated three complementary approaches: untargeted metabolite profiling by ultra-high-performance liquid chromatography coupled to tandem mass spectrometry (UHPLC–MS/MS), in vitro enzyme inhibition assays, and computational molecular modeling including docking and molecular dynamics simulations. This triangulated strategy is increasingly the standard in natural products research, because no single technique can simultaneously answer the questions “what is in the plant,” “what does the extract do,” and “which molecules might plausibly be responsible.” By combining all three, the researchers were able to move from a fifty-five-metabolite chemical inventory to a shortlist of candidate bioactive compounds worth pursuing in follow-up studies.

The metabolomic analysis proved especially productive. Using UHPLC–MS/MS in both positive and negative ionization modes, the team tentatively annotated fifty-five metabolites in the resin, substantially expanding the known chemical repertoire of C. gileadensis. The annotation relied on matching accurate mass measurements, fragmentation patterns, and retention behavior against databases and reference literature, and the word “tentative” is doing real work here: in metabolomics, assignments made without isolating each compound and confirming it by nuclear magnetic resonance are provisional by convention. Nevertheless, the inventory sketched a picture of a resin dominated by a diverse suite of phenolic compounds, including flavonoids, phenolic acids, and proanthocyanidins, alongside the terpenoid constituents for which the Commiphora genus is already famous. Previous work on related species such as Commiphora myrrha and Commiphora opobalsamum has yielded furanosesquiterpenoids, cadinane-type sesquiterpenes, cycloartane triterpenes, and lignans, and the new data suggest the balsam tree’s resin shares both overlapping and distinctive chemistry.

Parallel to the profiling, the researchers prepared an ethanolic extract of the resin and tested it against four human enzymes of clinical interest. Two of these, α-glucosidase and α-amylase, are central to carbohydrate digestion. α-Amylase breaks down long starch molecules into shorter oligosaccharides in the mouth and small intestine, while α-glucosidase finishes the job by cleaving disaccharides into absorbable glucose. Inhibiting these enzymes moderates the post-meal spike in blood glucose, which is precisely the mechanism behind widely prescribed antidiabetic drugs such as acarbose. The extract inhibited α-glucosidase with a half-maximal inhibitory concentration (IC50) of 6.18 micrograms per milliliter and α-amylase with an IC50 of 22.33 micrograms per milliliter, indicating meaningful potency in vitro, and a notable preference for the intestinal enzyme over the pancreatic one. That preference matters, because excessive α-amylase inhibition can cause gastrointestinal side effects from undigested starch fermentation, so inhibitors that spare α-amylase while potently blocking α-glucosidase are often considered a favorable pharmacological profile.

The extract also showed measurable inhibition of acetylcholinesterase and butyrylcholinesterase, the two enzymes that terminate cholinergic neurotransmission by hydrolyzing acetylcholine in the synaptic cleft. Cholinesterase inhibitors are a mainstay of symptomatic treatment in Alzheimer’s disease, and the rationale for testing them here goes beyond opportunism. Type 2 diabetes and Alzheimer’s disease are increasingly viewed as mechanistically intertwined; some researchers have gone so far as to label Alzheimer’s “type 3 diabetes,” citing shared disturbances in glucose metabolism, oxidative stress, and insulin signaling in the brain. Compounds that simultaneously temper carbohydrate absorption and support cholinergic function have therefore attracted attention as bifunctional leads, and the researchers explicitly designed their assay panel with this dual rationale in mind.

To identify which of the resin’s constituents might underlie these activities, the team undertook classical phytochemical isolation and succeeded in purifying three well-known plant secondary metabolites: gallic acid, a simple trihydroxybenzoic acid; quercetin, one of the most ubiquitous flavonols in the plant kingdom; and naringenin, a citrus-associated flavanone. Each purified compound was then tested against all four enzymes, and a clear hierarchy emerged. Quercetin was the most active across the board, inhibiting all four enzymes most strongly; naringenin was moderately active; and gallic acid, despite its phenolic hydroxyl richness, was the least potent of the three. This outcome is consistent with a growing literature. Quercetin’s five hydroxyl groups and conjugated carbonyl system allow extensive hydrogen bonding and π-stacking interactions with enzyme active sites, and it has previously been characterized as a bifunctional anti-cholinesterase and anti-glucosidase agent in independent in vitro and in silico screens. Naringenin, which carries one fewer hydroxyl and a more open flavanone framework, generally shows weaker but non-negligible binding, while small phenolic acids like gallic acid tend to lack the steric bulk to engage the deeper, more hydrophobic pockets of these enzymes.

The computational arm of the study aimed to explain these patterns at the atomic level. The researchers docked representative resin metabolites, including procyanidin B1, quercetin, sesamin, and commiferin, into four modeled human enzyme targets corresponding to the in vitro assays. Molecular docking predicts the preferred binding pose and estimated affinity of a small molecule within a protein’s active site by sampling orientations and scoring intermolecular contacts. The team then subjected selected docked complexes to molecular dynamics simulations, which allow the protein and ligand to flex and rearrange over time under physical force fields, providing a more realistic picture of whether a docked pose is stable or an artifact of the rigid starting structure. The simulations generated plausible pose-retention hypotheses for several metabolites across the four targets, suggesting that these compounds can form persistent interactions within the catalytic and peripheral binding regions of the enzymes.

The authors, however, insert an important caveat that deserves equal billing with the headline numbers. The docking targets they modeled are not species-matched to the enzymes used in the in vitro assays; in other words, the computational work was performed on human enzyme structures while some of the inhibitory data may derive from enzymes of different origin, a well-known confound in enzyme inhibition studies, since inhibitor potency can vary dramatically depending on the source species of the enzyme. The researchers therefore state explicitly that the docking and dynamics findings should not be regarded as direct confirmation of the experimental mechanism of action. This kind of methodological honesty is uncommon and valuable: it distinguishes between a consistent, suggestive story and a demonstrated causal chain, and it identifies exactly what the next experiment must be, namely assay-matched inhibition studies in which the same enzyme preparation is used for both the wet-lab measurement and the computational model.

The authors extend the same caution to the therapeutic interpretation of their results. The study, they write, does not establish antidiabetic efficacy, neuroprotection, synergistic action between the resin’s components, or confirmed engagement of the putative molecular targets in living systems. In vitro IC50 values are measured against isolated enzymes in buffered solutions, a context stripped of the absorption, metabolism, distribution, and clearance processes that determine whether an orally consumed plant extract can ever deliver its constituents to a target tissue in sufficient concentration. Recent animal work offers tantalizing support, with independent studies reporting that C. gileadensis extracts reduced blood glucose, HbA1c, and altered lipid profiles in diabetic mice, in one case comparable to metformin, but bridging from enzyme assays and rodent models to demonstrated clinical benefit remains the longest and most failure-prone stretch of the drug development pipeline.

What the study does accomplish is threefold. It dramatically expands the annotated chemical space of a historically important but under-characterized medicinal resin, providing a fifty-five-entry metabolite inventory that future researchers can mine. It provides quantitative in vitro evidence that the resin’s enzyme-inhibitory reputation has a plausible chemical basis, with quercetin emerging as the standout contributor and oligomeric procyanidins such as procyanidin B1 flagged as promising additional candidates. And it applies a transparent, computationally supported prioritization framework that names exactly which metabolites warrant assay-matched validation next. In doing so, the work transforms an ancient remedy from a matter of folklore into a well-defined research problem, one in which the molecules responsible for activity are no longer hypothetical but isolated, measured, and modeled, waiting for the next round of experiments to determine whether the balsam tree’s传奇 legacy has a molecular future.

The mounting prevalence of complex diseases has sparked the quest for novel therapeutic agents, particularly those that can target specific biomolecular pathways. CERS2 plays a crucial role in the metabolism of sphingolipids, which are vital for cellular signaling and membrane structure. Dysregulation of sphingolipid metabolism has been implicated in diverse pathological conditions, necessitating the identification of selective inhibitors capable of modulating CERS2 activity. This research not only illuminates the molecular landscape surrounding CERS2 but also opens new avenues for developing targeted therapies.

The team’s methodology employed structure-based virtual screening as a core component of their strategy. This technique utilizes the three-dimensional structures of biological macromolecules, allowing researchers to virtually assess and predict interactions between potential drug candidates and their targets. By meticulously analyzing the active site of CERS2, the researchers identified multiple hit compounds that demonstrated promising affinities. This innovative blend of technology and biology is indicative of modern drug discovery paradigms, where computational tools enhance the efficiency and effectiveness of the research process.

Following the identification of hit compounds, molecular dynamics simulations were employed to probe the stability and binding characteristics of these candidates within the CERS2 active site. This approach provides insights into the dynamic behavior of the enzyme-ligand complex, shedding light on how these compounds might behave within a biological context. Molecular dynamics simulation not only serves as a predictive tool but also extends our understanding of protein-ligand interactions, ultimately aiding in the design of more effective inhibitors.

An important aspect of this research lies in the validation of the identified candidates. While virtual screening and simulations provide robust preliminary data, experimental validation is essential to ascertain the biological relevance of the findings. This aspect of drug discovery underscores the importance of multidisciplinary collaboration, as theoretical insights must be substantiated through rigorous laboratory experiments. The integration of computational predictions with empirical results is fundamental to moving from the bench to the clinic.

Moreover, the implications of discovering a CERS2 inhibitor are substantial. Inhibiting CERS2 could provide a novel strategy for combating various cancer types that exploit sphingolipid metabolism. Identifying small molecules that selectively inhibit this enzyme could revolutionize treatment approaches for patients, potentially leading to improved survival rates and minimized side effects. Furthermore, targeting CERS2 could also impact metabolic disorders, where dysregulated sphingolipid metabolism contributes to pathophysiology.

This research exemplifies the potent combination of computational and experimental techniques in the age of precision medicine. As the field continues to evolve, the integration of artificial intelligence and machine learning into drug discovery workflows heralds a new frontier in biomedical research. The ability to predict and model complex biological interactions opens doors to a more personalized approach to therapy, tailoring treatments to individual molecular profiles.

The study’s findings also contribute to the growing body of literature that supports the use of virtual screening in drug discovery. By showcasing the effectiveness of this approach, the research provides a scalable model that can be employed in future investigations targeting various enzymes and receptors. The success of this study could inspire further exploration of other potential inhibitors in different biological contexts, thereby expanding the toolkit available to researchers in pharmaceuticals and therapeutics.

Furthermore, the challenges faced during the drug discovery process remain significant. The path from initial discovery to clinical use is fraught with hurdles, including optimizing compound efficacy and minimizing toxicity. The collaboration between computational chemists, biologists, and clinicians will be essential in navigating this complex landscape. Efforts must be made to forge partnerships that bridge gaps between disciplines, ensuring a holistic approach to drug development.

As the scientific community continues to unravel the complexities of cellular signaling pathways, it is imperative to maintain a focus on translational research. The identification of a CERS2 inhibitor not only serves as a testament to the power of modern technology but also highlights the potential of interdisciplinary research in addressing unmet medical needs. By transforming theoretical findings into practical applications, researchers can bring forward innovative solutions that improve patient outcomes.

Ultimately, the discovery of a potential CERS2 inhibitor represents a significant milestone in the ongoing quest for targeted therapies. This research not only adds to our understanding of sphingolipid metabolism but also exemplifies how computational approaches can enhance the drug discovery pipeline. As we move forward, embracing technological advances while fostering collaborations across disciplines will be crucial in translating scientific discoveries into real-world treatments that benefit society.

The research conducted by Yu and colleagues serves as a rallying cry for the scientific community, demonstrating the vast potential inherent in the confluence of computational modeling and empirical investigation. With the ongoing commitment to exploring the intricacies of biological systems, we are poised on the brink of transformative discoveries that could redefine our approach to treating some of the most challenging diseases of our time.

In conclusion, the discovery of a CERS2 inhibitor not only sets the stage for the development of new therapeutic agents but also reinforces the importance of a synergistic approach in modern research. By leveraging the strengths of computational and experimental methodologies, researchers are equipped to tackle the complexities of human health, paving the way for breakthroughs that can change lives.

Subject of Research: Inhibition of Ceramide Synthase 2 (CERS2)

Article Title: Discovery of a potential CERS2 inhibitor: hit compound identification via structure-based virtual screening and molecular dynamics simulations.

Article References:

Yu, B., Mo, S., Chen, Y. et al. Discovery of a potential CERS2 inhibitor: hit compound identification via structure—based virtual screening and molecular dynamics simulations.
Mol Divers (2026). https://doi.org/10.1007/s11030-025-11436-8

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s11030-025-11436-8

Keywords: CERS2, ceramide synthase, drug discovery, virtual screening, molecular dynamics simulations, targeted therapy, sphingolipids.

GPCRs represent the largest family of membrane receptors and are targets for roughly one-third of all marketed drugs, mediating a broad spectrum of physiological responses. Despite extensive study, the molecular underpinnings of how structurally distinct ligands produce differential signaling responses through the same receptor have remained obscure. Traditional structural methods typically capture static snapshots under equilibrium conditions, missing critical transient conformations that may govern signaling dynamics.

To bridge this knowledge gap, the investigative team focused on the MOR bound to three types of ligands categorized as partial, full, and super-agonists—each producing distinct degrees of receptor activation and downstream signaling. By applying TR cryo-EM to samples rapidly progressing through GTP-induced activation of the heterotrimeric G protein Gi (Gαiβγ), they visualized ensembles of receptor-G protein complexes at discrete time points, effectively generating snapshots of the activation trajectory in real time.

Remarkably, this technique uncovered a series of intermediate states previously undetected in static structural studies. Among these, one intermediate state provided crucial evidence linking receptor dynamics in transmembrane helices 5 and 6 to ligand efficacy. Notably, ligands with higher efficacy induced greater conformational flexibility within these helices, suggesting that dynamic structural plasticity is a key determinant of productive G-protein coupling and activation.

The findings also reveal ligand-dependent differences in state occupancy, signifying that ligands modulate the energy landscape of receptor conformations, thereby altering the population distribution of signaling states. This adds new dimension to the classic pharmacological concept of efficacy by presenting a structural correlate: more efficacious ligands promote receptor states that favor faster and more robust G-protein activation.

Furthermore, by extending their analysis to compare the GTP-dependent activation mechanisms of Gi versus Gs protein families, the researchers illuminated fundamental mechanistic disparities that likely account for their distinct kinetics and signaling profiles. These insights have profound implications for understanding biased agonism and selective therapeutic targeting of GPCRs.

Corroborated by extensive molecular dynamics (MD) simulations, the experimental data emphasize how receptor flexibility modulates the allosteric communication between ligand-binding pockets and intracellular signaling interfaces. The simulations align with TR cryo-EM observations, highlighting increased mobility in TM helices corresponding to higher ligand efficacy states. This synergy between structural snapshots and computational modeling presents a powerful framework for comprehending GPCR dynamics.

Complementing the structural and computational work, single-molecule fluorescence resonance energy transfer (smFRET) assays provided real-time kinetic data, bringing temporal resolution to the conformational transitions of receptor and G-protein complexes. These measurements support the notion that partial agonists may induce kinetic traps—intermediate states that slow G-protein activation without fully stabilizing the active receptor conformation—shedding light on the molecular basis of partial signaling efficacy.

Overall, this study marks a significant leap in GPCR research by establishing a mechanistic relationship between ligand binding, receptor conformational dynamics, and G-protein activation kinetics. The ability to capture non-equilibrium states through TR cryo-EM opens new vistas for drug discovery, permitting the design of ligands that finely tune receptor function via targeted modulation of conformational landscapes.

The implications of this work extend well beyond opioid pharmacology. Given the ubiquity of GPCRs in human physiology, understanding the kinetic and dynamic aspects of receptor activation can revolutionize approaches to treating myriad conditions, from metabolic diseases to neurological disorders. Furthermore, it challenges the conventional equilibrium-centric paradigms, emphasizing the importance of temporal dynamics in receptor pharmacology.

Intriguingly, these findings also inspire the notion of ‘kinetic pharmacology,’ where the timescales of receptor state transitions become as critical as thermodynamic stability, adjusting how we think about agonist design and receptor signaling bias. By exploiting transient intermediates and dynamic landscapes, drug developers might now craft molecules with desired kinetic profiles, optimizing therapeutic efficacy and minimizing side effects.

This research leverages state-of-the-art cryo-EM instrumentation capable of freezing biological complexes at precise time intervals following ligand-induced activation events. The capability to image assemblies at sub-millisecond to millisecond timescales is revolutionizing the structural biology field, transforming once invisible transient intermediates into visualized entities.

In summary, this multidisciplinary investigation provides a blueprint for integrating experimental and computational approaches to dissect the complex choreography of receptor activation. It uncovers the hidden mechanistic subtleties that govern how distinct ligands shape GPCR signaling, offering a transformative outlook on receptor pharmacology and opening pathways toward rational drug design strategies informed by structural dynamics rather than static snapshots.

As opioid therapies remain both critically important and therapeutically challenging due to side effects and tolerance development, such detailed mechanistic insights into MOR function could facilitate the creation of safer analgesics. By harnessing the dynamic interplay of receptor conformations and ligand efficacy, future drugs may achieve greater specificity in modulating pain pathways while minimizing adverse effects.

The scientific community now stands at the cusp of a new era where non-equilibrium structural biology, empowered by TR cryo-EM and allied technologies, will unravel the complexities of cellular signaling. This breakthrough paves the way for developing next-generation therapeutics designed with exquisite precision to modulate receptor states dynamically, potentially revolutionizing treatment paradigms across diseases driven by GPCR dysfunction.

Subject of Research:
Molecular mechanisms of ligand-dependent activation of the μ-opioid receptor and conformational dynamics of G-protein coupling.

Article Title:
Non-equilibrium snapshots of ligand efficacy at the μ-opioid receptor.

Article References:
Robertson, M.J., Modak, A., Papasergi-Scott, M.M. et al. Non-equilibrium snapshots of ligand efficacy at the μ-opioid receptor. Nature (2025). https://doi.org/10.1038/s41586-025-10056-4

Image Credits:
AI Generated

Understanding why certain plastics stick effectively to metals while others do not requires an in-depth look at the molecular scale. The Osaka Metropolitan researchers focused on polyamides (PAs), commonly known as nylons, which are frequently used plastics known for their mechanical resilience and chemical versatility. They explored two different polyamide types: PA6, characterized by a flexible aliphatic backbone, and PAMXD6, notable for its rigid aromatic ring structure. These polymers were studied in combination with alumina surfaces, a common metal oxide found in aluminum alloys, which serves as a representative model for metal substrates.

A crucial factor in this polymer-metal interaction is the chemistry of the alumina surface, specifically whether it terminates with hydroxyl groups (OH-terminated) or remains non-hydroxylated. This termination dictates the chemical environment that polymer chains encounter upon contact. Hydroxylated surfaces present reactive sites that can form hydrogen bonds and other interactions with polymer chain segments, whereas non-hydroxylated surfaces offer a less interactive interface. Through simulations, the team categorized polymer chain sections into “trains,” regions adsorbed flat on the surface; “loops,” non-adsorbed segments spanning between trains; and “tails,” the free ends extending away from the surface.

Simulating tensile strain applied to the polymer-alumina interface allowed the researchers to probe the mechanical properties of these bonds down to atomic rearrangements—a phenomenon known as yielding. Yielding marks a critical threshold where irreversible changes occur in the interface structure, affecting long-term durability. Before yielding, the mechanical response is governed primarily by the intrinsic chemical composition of the polymer. The aromatic PAMXD6 chains exhibit higher stiffness and a greater ability to resist deformation compared to the more flexible PA6, indicating that polymer backbone rigidity plays a major role in elastic behavior.

However, the picture shifts dramatically after yielding. On hydroxylated alumina surfaces, PAMXD6 chains tend to detach from the surface, a process called desorption, indicating weaker post-yield adhesion. Contrarily, the PA6 polymer shows a remarkable ability to reconfigure its conformation: loops transform into stretched tails, which maintain intimate contact with the surface and prevent full detachment. This adaptability highlights how flexible polymer chains can sustain adhesion under stress via dynamic restructuring at the interface. On non-hydroxylated surfaces, both polymers retain solid attachment through persistent trains and loops, illustrating the pivotal role surface chemistry plays in adhesion stability.

These findings not only identify the chemical-functional relationship that dictates metal-polymer adhesion strength but also have profound practical implications. By understanding the interplay between polymer conformational dynamics and surface termination, materials scientists can rationally design polymer-metal interfaces with targeted performance attributes. This approach reduces reliance on costly and time-consuming trial-and-error experiments traditionally used in developing metal-plastic hybrids. Selecting specific polymer chemistries and applying appropriate surface treatments can optimize joint strength, resilience, and longevity in structural applications.

The implications extend far beyond adhesion science. Lightweight polymer-metal hybrid materials are game-changers for reducing vehicle mass, enhancing fuel efficiency, and ultimately lowering emissions—a cornerstone of sustainable transportation. With carbon neutrality becoming a global mandate, these material innovations align perfectly with environmental goals. The research conducted by Osaka Metropolitan University represents a vital step toward integrated, mechanism-based design strategies that will unlock new performance horizons for automotive, aerospace, and consumer electronics industries.

This breakthrough was achieved through the sophisticated use of computational molecular dynamics simulations, a powerful method that provides atomic-level resolution of materials behavior unattainable by traditional experimental techniques alone. Such simulations enable researchers to visualize and quantify not only static structures but also dynamic processes, such as chain movement and bond breakage, under realistic conditions including applied mechanical load. This virtual microscope approach accelerates material discovery and elucidates fundamental phenomena inherent to complex hybrid interfaces.

Takuya Kuwahara, the study’s lead author, emphasized the significance of their findings in understanding and controlling adhesive mechanisms at the molecular scale. Their research confirms that the intrinsic stiffness of polymer backbones and the chemical composition of metal surfaces collectively dictate adhesion behavior before and after materials yield under stress. They demonstrated that flexible polymers are better suited to sustain bonding on reactive hydroxylated surfaces through molecular reorganization, whereas rigid polymers perform better on less reactive, non-terminated surfaces.

Overall, this groundbreaking study provides a comprehensive, hierarchical view of polymer-alumina bonding across multiple length scales, bridging chemistry, mechanics, and molecular physics. The insights gained pave a clear path for the next generation of polymer-metal hybrid materials that are not only stronger and lighter but also more sustainable. As industries strive to meet ambitious emission reduction targets, the ability to engineer joints explicitly from a fundamental understanding of microscopic adhesion mechanisms represents a transformative advance.

In conclusion, Osaka Metropolitan University’s research heralds an exciting era wherein molecular simulations translate into tangible, real-world materials innovation. The synergy between polymer design and surface engineering, grounded in atomic-level comprehension, will enable lightweight, durable, and environmentally responsible hybrid structures critical for the future of transportation and beyond. This work serves as a clarion call for concerted multidisciplinary efforts to harness chemistry and mechanics in crafting the materials of tomorrow.

Subject of Research: Not applicable
Article Title: Chemical Functionalities Govern Polyamide–Alumina Adhesion through Local Conformational Dynamics
News Publication Date: 10-Nov-2025
References: DOI: 10.1038/s43246-025-00977-y
Image Credits: Osaka Metropolitan University

Keywords

Polymer-metal adhesion, molecular dynamics simulation, polyamide, alumina surface, polymer conformation, material interface, sustainable materials, lightweight composites, vehicle materials, molecular mechanics, surface chemistry, hybrid materials

Folding of RNA into stable and functional configurations involves complex intramolecular interactions that yield characteristic secondary and tertiary structures. These structures are critical because they dictate RNA’s ability to interact with other biomolecules and execute its biological roles. While experimental methods such as X-ray crystallography and nuclear magnetic resonance can provide snapshots of these structures, they are labor-intensive and sometimes fail to capture dynamic folding processes. Consequently, molecular dynamics (MD) simulations have become a powerful computational tool for investigating RNA folding, enabling researchers to model the movement of atoms over time under defined physical laws.

Despite advances, simulating the full folding process of RNA molecules starting from an unfolded chain to their native conformation remains notoriously difficult. Standard MD simulations require extensive computational resources due to the sheer number of atoms involved and the prolonged timescales needed to observe folding, often beyond what is feasible with explicit solvent models where every water molecule and ion is individually represented. This limitation has historically confined successful folding simulations to small, simple RNA motifs, typically short stem-loop structures comprising approximately ten nucleotides.

In this groundbreaking research spearheaded by Associate Professor Tadashi Ando at Tokyo University of Science, Japan, a paradigm shift in RNA folding simulations has been achieved. The study employed a hybrid computational approach, combining an advanced atomistic force field named DESRES-RNA, which meticulously represents atomic interactions in RNA molecules, with the GB-neck2 generalized Born implicit solvent model. This solvent model abstracts the aqueous environment as a continuous medium rather than discrete molecules, significantly accelerating the conformational sampling process without substantial compromise in accuracy.

Dr. Ando’s team applied this innovative computational framework to an unprecedentedly diverse library of 26 RNA stem-loop constructs. These molecules varied broadly in size, from 10 to 36 nucleotides, and included structural features such as bulges and internal loops which add complexity to folding dynamics. Importantly, all simulations initiated from fully extended, unfolded configurations, simulating the entire trajectory of folding rather than shortcuts from partially folded states. This rigor provided a stringent test of the model’s predictive power.

The results were remarkably encouraging: 23 out of 26 RNA molecules folded into their experimentally determined native-like conformations. The fidelity of these folds was quantified using root mean square deviation (RMSD) metrics comparing simulation outcomes to known structures. For the simpler stem-loop RNAs, RMSD values were impressively low, under 2 angstroms for the stem regions, and remained below 5 angstroms over the full molecule, signaling high structural accuracy. These findings demonstrate that the integrated DESRES-RNA force field and GB-neck2 solvent approach can reliably replicate the native folding pathways of structurally diverse RNA sequences.

The study also tackled more challenging RNA motifs featuring bulges and internal loops, common in functional RNAs such as ribozymes and riboswitches. Of the eight complex structures studied, five reached their correct fold, an achievement that surpasses previous MD simulation capabilities for such systems. The simulations also unveiled distinct folding pathways unique to these motifs, offering unprecedented insights into the mechanistic routes RNA molecules traverse during folding.

While largely successful, the research highlighted areas needing further refinement. Particularly, the loop regions of the RNA molecules exhibited somewhat less precision with RMSD values nearing 4 angstroms, indicating room for improvement in modeling non-canonical base pairing and the nuanced electrostatic environment. Additionally, the implicit solvent model presently overlooks critical effects of divalent cations like magnesium ions, which substantially stabilize RNA tertiary structures and influence folding kinetics. Optimizing the interaction parameters for these ions and loop dynamics could enhance simulation fidelity further.

The significance of this achievement stretches beyond academic interest. Reliable RNA folding simulations pave the way for rational design of RNA molecules for therapeutic and biotechnological applications. For instance, understanding the folding process aids in developing RNA-targeting drugs capable of combating viral infections such as COVID-19 and influenza, or correcting genetic mutations linked to various diseases and cancers. The ability to predict RNA folding from sequence alone enables predictive screening and optimization without heavy reliance on experimental trial-and-error.

Associate Professor Ando emphasizes the impact of this milestone: “Reproducing the overall folding of basic stem-loop structures with such accuracy marks a new era in the computational exploration of RNA biology. These methods empower scientists to probe not just static structures, but also the dynamic behaviors integral to RNA function. I anticipate expanding applications from molecule design to drug discovery soon.” This study sets a robust computational benchmark, inspiring future innovations that will deepen our molecular understanding and therapeutic targeting of RNA.

The combination of atomistic force fields with efficient implicit solvent models, as demonstrated in this study, offers a promising path forward for molecular simulations. Expanding simulation libraries to include broader RNA classes and refining solvent models will be crucial next steps. Collaborations integrating experimental data and machine learning methodologies could also accelerate improvements, yielding more reliable, scalable simulations to decode the RNA folding code comprehensively.

In summary, through computational ingenuity and rigorous validation, Associate Professor Tadashi Ando’s research marks a transformative leap in modeling RNA folding. The ability to simulate complex RNA stem loops accurately from unfolded states unlocks the potential for high-resolution mechanistic understanding and innovative RNA-based therapeutics, heralding a new chapter in molecular biology and biomedicine.

Subject of Research:
Not applicable

Article Title:
Molecular Dynamics Simulations of RNA Stem-Loop Folding Using an Atomistic Force Field and a Generalized Born Implicit Solvent

News Publication Date:
26-Oct-2025

Web References:
https://pubs.acs.org/doi/10.1021/acsomega.5c05377

References:
DOI: 10.1021/acsomega.5c05377

Image Credits:
Associate Professor Tadashi Ando, Tokyo University of Science, Japan

Keywords:
Bioengineering, Biotechnology, Genetic material, RNA, Life sciences, Drug development, Drug design

Molecular dynamics (MD) simulations have been a cornerstone of computational chemistry and materials science, allowing scientists to explore molecular behavior with unprecedented precision. However, these simulations are often limited by the computational resources they require, making them time-consuming and expensive. Traditional methods face challenges in scaling up to larger systems or longer timescales, where critical phenomena often occur. This limitation has spurred researchers to seek alternative strategies for improving simulation efficiency, leading to the innovative breakthrough presented in this study.

At the heart of the researchers’ approach is the fundamental concept of “flow.” By drawing parallels between the movement of molecules in a system and the behavior of fluids, the team proposes a framework that optimizes the representation of molecular interactions. This perspective not only enhances the speed of calculations but also provides more accurate results, particularly in complex systems where minute interactions can have significant impacts. The researchers utilize advanced mathematical formulations to transform conventional MD methods, integrating equations from fluid dynamics that account for collective behavior, thereby allowing for faster resolution of molecular trajectories.

The implications of these findings are vast. For one, they could enable the simulation of larger and more complex systems that were previously beyond computational reach. Imagine simulating entire biological processes, such as protein folding or drug interactions, with a level of detail that captures the subtleties of molecular behavior over time. This could accelerate the drug discovery process and provide deeper insights into biological functions, ultimately leading to breakthroughs in medicine and biochemistry.

In their study, Ismail and his colleagues also address the importance of benchmarking their new technique against established methods. By rigorously testing their approach across various scenarios and comparing the results, they demonstrate that their method not only maintains accuracy but significantly reduces computational overhead. This rigorous validation underscores the reliability of their technique, making it an attractive option for researchers across multiple disciplines.

As computational power continues to grow, the need for methodologies that can effectively harness that power becomes paramount. The approach proposed in this study integrates seamlessly with current computational infrastructures, allowing researchers to adopt it without the need for extensive retraining or software modifications. This ease of implementation is crucial for widespread adoption within the scientific community, which often grapples with the inertia of traditional practices.

Another compelling aspect of this research is its potential to inform other fields. Beyond chemistry and materials science, the principles derived from this study may have applications in fields ranging from environmental science to astrophysics. For example, understanding fluid-like behavior in molecular systems could enhance models of planetary atmospheres or ocean currents, offering new perspectives on climate dynamics. The methodologies established here could thus serve as a foundation for cross-disciplinary collaboration, fostering innovation that transcends traditional boundaries.

The researchers also ponder the future ramifications of their findings. As artificial intelligence and machine learning become increasingly integrated into scientific research, the concepts from their study could be utilized to train algorithms capable of predicting molecular behavior with unprecedented accuracy. By providing a more intuitive understanding of molecular interactions, this research can help develop AI systems that further automate and optimize molecular simulations, potentially revolutionizing the field.

With climate change and global health crises place unprecedented demands on science, methodologies that accelerate research processes are urgently needed. The findings from Ismail, Martin, and Butler represent a significant contribution toward meeting these challenges. By bridging the gap between theory and practice, their work provides a viable path for scientists to explore complex systems while navigating the constraints of time and computational resources.

Moreover, as industries increasingly consist of complex systems, from pharmaceuticals to materials manufacturing, the practical implications of this research could foster economic growth through quicker product development cycles. Companies that adopt these new methods may gain a competitive edge in their respective fields, positioning themselves as leaders in innovation.

On a fundamental level, this research not only advances the field of molecular dynamics but also prompts a reevaluation of the foundational principles guiding scientific inquiry. By embracing fluid dynamics concepts and applying them to molecular interactions, the authors encourage a shift toward more holistic approaches in research. This paradigm shift emphasizes the importance of interdisciplinary thinking, leveraging insights from diverse fields to solve persistent problems in science.

In conclusion, this study heralds a new era in molecular dynamics simulations, offering a significant leap forward in how scientists engage with complex biological and chemical systems. Ismail, Martin, and Butler have laid the groundwork for subsequent exploration, opening the door for novel applications and innovations that can enhance our understanding of the microscopic world. As we stand on the brink of this new frontier, the ripple effects of their findings may very well echo throughout the scientific community and beyond for years to come.

Subject of Research: Molecular dynamics simulations, fluid dynamics concepts

Article Title: Accelerating molecular dynamics by going with the flow

Article References:

Ismail, A.Y., Martin, B.A.A. & Butler, K.T. Accelerating molecular dynamics by going with the flow.
Nat Mach Intell (2025). https://doi.org/10.1038/s42256-025-01129-0

Image Credits: AI Generated

DOI:

Keywords: Molecular dynamics, fluid dynamics, computational chemistry, simulation speed, interdisciplinary research, drug discovery, artificial intelligence